keyword
https://read.qxmd.com/read/38639184/cetuximab-chemotherapy-resistance-insight-into-the-homeostatic-evolution-of-head-and-neck-cancer-review
#21
JOURNAL ARTICLE
Carlos Henrique De Paula Diniz, Tiago Henrique, Ana Carolina B Stefanini, Tialfi Bergamin De Castro, Eloiza H Tajara
The complex evolution of genetic alterations in cancer that occurs in vivo is a selective process involving numerous factors and mechanisms. Chemotherapeutic agents that prevent the growth and spread of cancer cells induce selective pressure, leading to rapid artificial selection of resistant subclones. This rapid evolution is possible because antineoplastic drugs promote alterations in tumor‑cell metabolism, thus creating a bottleneck event. The few resistant cells that survive in this new environment obtain differential reproductive success that enables them to pass down the newly selected resistant gene pool...
June 2024: Oncology Reports
https://read.qxmd.com/read/38638854/high-pd-l1-expression-on-immune-cells-along-with-increased-density-of-tumor-infiltrating-lymphocytes-predicts-a-favorable-survival-outcome-for-patients-with-loco-regionally-advanced-head-and-neck-cancer-early-results-from-a-prospective-study
#22
JOURNAL ARTICLE
Tomáš Blažek, Marek Petráš, Pavel Hurník, Petr Matoušek, Lukáš Knybel, Zuzana Zděblová Čermáková, Jan Štembírek, Jakub Cvek, Renata Soumarová
INTRODUCTION: In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. METHODS: To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38637744/the-effect-of-internet-administered-support-carer-esupport-on-preparedness-for-caregiving-in-informal-caregivers-of-patients-with-head-and-neck-cancer-compared-with-support-as-usual-a-study-protocol-for-a-randomized-controlled-trial
#23
JOURNAL ARTICLE
Birgitta Johansson, Åsa Cajander, Awais Ahmad, Emma Ohlsson-Nevo, Per Fransson, Brith Granström, Louise von Essen, Ulrica Langegård, Mona Pettersson, Anna Henriksson, Ylva Tiblom Ehrsson
BACKGROUND: Informal caregivers (ICs) of patients with cancer provide essential and mainly uncompensated care. A self-perceived preparedness to care for the patient is associated with a lower caregiver burden, described as the extent to which caregiving is perceived as having adverse effects on IC functioning and well-being. ICs' well-being is associated with patient-perceived quality of care, suggesting that interventions to optimize ICs' health are essential in order to improve patient care...
April 18, 2024: BMC Cancer
https://read.qxmd.com/read/38637150/current-and-future-directions-in-interventional-neuro-oncology-are-we-there-yet
#24
REVIEW
Yang Qiao, Maggie Xiong, Yi Jonathan Zhang, Samuel Tsappidi, Peter Kan, Clifford R Weiss, Ferdinand Hui, Stephen R Chen
Advancements in technology and technical expertise increasingly enable neurointerventionalists to deliver safer and more effective endovascular treatments to cancers of the brain, spine, head, and neck. In addition to established neuro-oncological interventions such as pre-surgical tumor embolization and percutaneous ablation, newer modalities focused on direct arterial infusion of chemotherapy, radioisotopes, and radiosensitizers continue to gain traction as complementary treatment options, while stem cell-mediated delivery of theranostic nanoparticles and oncolytic virus are being explored for even greater specificity in targeting cancers across the blood-brain barrier...
April 18, 2024: Journal of Neurointerventional Surgery
https://read.qxmd.com/read/38636711/comparison-of-3-year-local-control-using-dahanca-radiotherapy-guidelines-before-and-after-implementation-of-five-millimetres-geometrical-gtv-to-high-dose-ctv-margin
#25
JOURNAL ARTICLE
Ruta Zukauskaite Ruta, Morten Horsholt Kristensen, Jesper Grau Eriksen, Jørgen Johansen, Eva Samsøe, Lars Johnsen, Camilla Kjær Lønkvist, Cai Grau, Christian Rønn Hansen
INTRODUCTION: Treatment planning using a five-millimetre geometrical margin from GTV to high-dose CTV (CTV1) has been used in DAHANCA treatment centres since 2013. We aimed to evaluate changes in CTV1 volumes, local control (LC), and recurrence pattern after the implementation of five-millimetre geometrical margins nationally. MATERIALS AND METHODS: 1,948 patients with pharyngeal, and laryngeal squamous cell carcinomas completed definitive IMRT-based treatment in 2010-2012 and 2013-2015 in three centres...
April 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38636710/re-irradiation-versus-systemic-therapy-for-the-management-of-local-regionally-recurrent-head-and-neck-cancer
#26
JOURNAL ARTICLE
Allen M Chen, Jeremy P Harris, Rupali Nabar, Tjoson Tjoa, Yarah Haidar, William B Armstrong
PURPOSE: The optimal management of local-regionally recurrent head and neck cancer that is not amenable to surgical resection is uncertain. We sought to compare outcomes among patients treated with and without re-irradiation in this setting. METHODS AND MATERIALS: A review of institutional registries identified 65 patients with local-regionally recurrent squamous cell carcinoma of the head and neck who were ineligible for surgery. Forty patients (62 %) opted for re-irradiation with the remaining 25 patients (38 %) undergoing initial systemic therapy alone...
April 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38636708/a-multicentric-randomized-controlled-phase-iii-trial-of-adaptive-and-18f-fdg-pet-guided-dose-redistribution-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-artforce
#27
JOURNAL ARTICLE
Anna Liza M P de Leeuw, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-Vân France Nguyen, Frank J P Hoebers, Ann Hoeben, Chris H J Terhaard, Lip Wai Lee, Signe Friesland, Roel J H M Steenbakkers, Lisa Tans, Jolien Heukelom, Mutamba T Kayembe, Simon R van Kranen, Harry Bartelink, Coen R N Rasch, Jan-Jakob Sonke, Olga Hamming-Vrieze
BACKGROUND AND PURPOSE: This multicenter randomized phase III trial evaluated whether locoregional control of patients with LAHNSCC could be improved by fluorodeoxyglucose-positron emission tomography (FDG-PET)-guided dose-escalation while minimizing the risk of increasing toxicity using a dose-redistribution and scheduled adaptation strategy. MATERIALS AND METHODS: Patients with T3-4-N0-3-M0 LAHNSCC were randomly assigned (1:1) to either receive a dose distribution ranging from 64-84 Gy/35 fractions with adaptation at the 10thfraction (rRT) or conventional 70 Gy/35 fractions (cRT)...
April 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38636587/target-delineation-in-postoperative-radiotherapy-for-head-and-neck-cancer-after-flap-reconstruction
#28
JOURNAL ARTICLE
Xuguang Scott Chen, David Sher, Christopher Blake Sullivan, Michael C Repka, Colette Shen, Bhisham Chera
No abstract text is available yet for this article.
April 16, 2024: Practical Radiation Oncology
https://read.qxmd.com/read/38635051/effect-of-radiotherapy-on-the-surface-roughness-and-microhardness-of-contemporary-bioactive-restorative-materials
#29
JOURNAL ARTICLE
Cansu Atalay, A Ruya Yazici
OBJECTIVE: The aim of this in vitro study was to evaluate the effect of radiotherapy on the surface microhardness and roughness of different bioactive restorative materials. MATERIALS AND METHODS: A total of 60-disc specimens (5 mm × 2 mm) were performed in four groups (n = 15 each) from Equia Forte HT, Cention N, Activa Bioactive Restorative, and Beautifil II. Following the polishing procedure (600, 1000, 1200 grit silicon carbide papers), all specimens were irradiated at 2 Gy per fraction, five times a week for a total dose of 70 Gy in 30 fractions over 7 weeks...
April 18, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38634434/impact-of-intraoperative-fluid-administration-and-complications-in-head-and-neck-cancer-free-flap-surgery-at-a-tertiary-care-hospital-of-a-low-and-middle-income-country
#30
JOURNAL ARTICLE
Waleed Bin Ghaffar, Faisal Shamim, Mujtaba Khalil, Moeed Bin Abdul Ghaffar, Tahir Munir
Perioperative fluid administration plays an essential role in head and neck cancer free flap surgery. The impact of intraoperative fluid administration on postoperative complications in head and neck cancer free flap surgery remains ill-defined. All adult patients who underwent a free flap surgery for head and neck cancer between January 2014 and December 2018 were included in the study. A total of 224 patients met the inclusion criteria. The mean age of patients was 45.0 years, and the majority were male (85...
April 18, 2024: Journal of Perioperative Practice
https://read.qxmd.com/read/38633973/blastoid-mantle-cell-lymphoma-presenting-as-an-oropharyngeal-mass
#31
Sharina Macapagal, Chalothorn Wannaphut, Toshiaki Takahashi, Thanaboon Yinadsawaphan, Yoshito Nishimura, Jared Acoba
Blastoid mantle cell lymphoma (MCL) is an extremely rare neoplasm with a dismal prognosis. MCL with an initial presentation in the oral cavity has been rarely reported. This report describes a 75-year-old male who presented with an oropharyngeal mass causing dysphonia and intermittent hypoxia. A biopsy and immunophenotyping confirmed MCL, favoring the blastoid variant. Imaging showed a 4.2 cm left oropharyngeal polypoid mass with extensive lymphadenopathy. His prognosis was considered unfavorable with elevated Ki-67 index, blastoid morphology, and p53 positivity of malignant cells...
March 2024: Curēus
https://read.qxmd.com/read/38632499/correction-pembrolizumab-based-first-line-treatment-for-pd-l1-positive-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-a-retrospective-analysis
#32
Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, Andrea Botticelli
No abstract text is available yet for this article.
April 17, 2024: BMC Cancer
https://read.qxmd.com/read/38632333/a-multi-cancer-early-detection-blood-test-using-machine-learning-detects-early-stage-cancers-lacking-uspstf-recommended-screening
#33
JOURNAL ARTICLE
Janet Vittone, David Gill, Alex Goldsmith, Eric A Klein, Jordan J Karlitz
US Preventive Services Task Force (USPSTF) guidelines recommend single-cancer screening for select cancers (e.g., breast, cervical, colorectal, lung). Advances in genome sequencing and machine learning have facilitated the development of blood-based multi-cancer early detection (MCED) tests intended to complement single-cancer screening. MCED tests can interrogate circulating cell-free DNA to detect a shared cancer signal across multiple tumor types. We report real-world experience with an MCED test that detected cancer signals in three individuals subsequently diagnosed with cancers of the ovary, kidney, and head/neck that lack USPSTF-recommended screening...
April 17, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38631709/preclinical-evaluation-of-two-phylogenetically-distant-arenavirus-vectors-for-the-development-of-novel-immunotherapeutic-combination-strategies-for-cancer-treatment
#34
JOURNAL ARTICLE
Josipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K Orlinger, Henning Lauterbach
BACKGROUND: Engineered arenavirus vectors have recently been developed to leverage the body's immune system in the fight against chronic viral infections and cancer. Vectors based on Pichinde virus (artPICV) and lymphocytic choriomeningitis virus (artLCMV) encoding a non-oncogenic fusion protein of human papillomavirus (HPV)16 E6 and E7 are currently being tested in patients with HPV16+ cancer, showing a favorable safety and tolerability profile and unprecedented expansion of tumor-specific CD8+ T cells...
April 17, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631537/radiation-induced-xerostomia-is-related-to-stem-cell-dose-dependent-reduction-of-saliva-production
#35
JOURNAL ARTICLE
Maria I van Rijn-Dekker, Sacha la Bastide-van Gemert, Monique A Stokman, Arjan Vissink, Robert P Coppes, Johannes A Langendijk, Peter van Luijk, Roel J H M Steenbakkers
BACKGROUND AND PURPOSE: Previous studies have shown that the mean dose to the parotid gland stem cell rich regions (Dmean,SCR ) is the strongest dosimetric predictor for the risk of patient-reported daytime xerostomia. This study aimed to test whether the relationship between patient-reported xerostomia and Dmean,SCR is explained by a dose-dependent reduction of saliva production. MATERIAL/METHODS: In 570 head and neck cancer patients treated with definitive radiation therapy (RT), flow from the parotid (FLOWPAR ) and submandibular/sublingual glands (FLOWSMSL ) and patient-reported daytime (XERDAY ) and nighttime xerostomia (XERNIGHT ) were prospectively measured before, and at 6 and 12 months after RT...
April 15, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38630333/trends-in-ototoxicity-monitoring-among-cisplatin-treated-patients-with-cancer
#36
JOURNAL ARTICLE
David S Lee, Emma Y Travis, Susan K Wong, Marie-Ange Munyemana, Lauren Mueller, Cathryn Collopy Rowling, Jason T Rich, Patrik Pipkorn, Sidharth V Puram, Ryan S Jackson, Douglas R Adkins, Peter Oppelt, Wade L Thorstad, Cameron C Wick, Jose P Zevallos, Kate McClannahan, Angela L Mazul
PURPOSE: This study aims to characterize patterns in ototoxicity monitoring and identify potential barriers to audiologic follow-up. METHODS: We performed a single-institution retrospective cohort study on adult (≥ 18 years old) cancer patients treated with cisplatin from January 2014 to September 2021. Our primary outcomes were rates of baseline and post-treatment audiograms at the following time points: 3, 6, 12, and greater than 12 months...
April 17, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38630265/expansion-of-tumor-infiltrating-lymphocytes-from-head-and-neck-squamous-cell-carcinoma-to-assess-the-potential-of-adoptive-cell-therapy
#37
JOURNAL ARTICLE
Sangjoon Choi, Mofazzal Hossain, Hyun Lee, Jina Baek, Hye Seon Park, Chae-Lyul Lim, DoYeon Han, Taehyun Park, Jong Hyeok Kim, Gyungyub Gong, Mi-Na Kweon, Hee Jin Lee
BACKGROUND: Adoptive transfer of in vitro expanded tumor-infiltrating lymphocytes (TILs) has been effective in regressing several types of malignant tumors. This study assessed the yield and factors influencing the successful expansion of tumor-infiltrating lymphocytes (TILs) from head and neck squamous cell carcinoma (HNSCC), along with their immune phenotypes. METHODS: TILs were expanded from 47 surgically resected HNSCC specimens and their metastasized lymph nodes...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38630141/metastatic-cutaneous-squamous-cell-carcinoma-accounts-for-nearly-all-squamous-cell-carcinomas-of-the-parotid-gland
#38
REVIEW
Patrick J Bradley, Göran Stenman, Lester D R Thompson, Alena Skálová, Roderick H W Simpson, Pieter J Slootweg, Alessandro Franchi, Nina Zidar, Alfons Nadal, Henrik Hellquist, Michelle D Williams, Ilmo Leivo, Abbas Agaimy, Alfio Ferlito
Primary squamous cell carcinoma of the parotid gland (pSCCP) has long been recognized as a separate entity and is included in the WHO classifications of salivary gland tumors. However, it is widely accepted among head and neck pathologists that pSCCP is exceptionally rare. Yet, there are many publications describing series of pSCCP and data from SEER and other cancer register databases indicate erroneously an increasing incidence of pSCCP. Importantly, pSCCP and metastatic (secondary) squamous cell carcinoma to the parotid gland (mSCCP) have nearly identical histological features, and the diagnosis of pSCCP should only be made after the exclusion of mSCCP...
April 17, 2024: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/38623570/early-growth-response-1-regulates-dual%C3%A2-specificity-protein-phosphatase-1-and-inhibits-cell-migration-and-invasion-of-tongue-squamous-cell-carcinoma
#39
JOURNAL ARTICLE
Longxun Zhou, Yuqun Shan, Jun Li, Min Li, Zhen Meng, Na Guo
Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors in the head and neck, and among the OSCCs, tongue squamous cell carcinoma (TSCC) is one of the most common types. Although therapy strategies have recently advanced, the prognosis of TSCC has not substantially improved. Metastasis is one of the main causes of patient mortality in TSCC; therefore, it is necessary to elucidate the mechanism by which TSCC metastasis is regulated. In the present study, the early growth response 1 (Egr-1) expression in TSCC was analyzed based on GEO datasets and the effect of Egr-1 in TSCC tumor cell migration and invasion was measured using Transwell assay...
June 2024: Oncology Letters
https://read.qxmd.com/read/38621326/addressing-positive-multi-cancer-early-detection-tests-in-head-and-neck-surgery-experience-with-head-and-neck-work-up-for-high-risk-referrals
#40
JOURNAL ARTICLE
Forrest W Fearington, Conan Y Zhao, Santiago Romero-Brufau, Eric J Moore, Daniel L Price, Kendall K Tasche, Linda X Yin, Elizabeth T Kunkel, John B Kisiel, Karthik V Giridhar, David M Routman, Kathryn M Van Abel
OBJECTIVES: Blood-based multi-cancer early detection (MCED) tests are now commercially available. However, there are currently no consensus guidelines available for head and neck cancer (HNC) providers to direct work up or surveillance for patients with a positive MCED test. We seek to describe cases of patients with positive MCED tests suggesting HNC and provide insights for their evaluation. METHODS: Retrospective chart review of patients referred to Otolaryngology with an MCED result suggesting HNC...
April 14, 2024: Oral Oncology
keyword
keyword
159867
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.